Liquid biopsy-guided genomic studies performed in colorectal cancer have demonstrated a significant increase in RAS mutant clones in plasma at the onset of secondary resistance to anti-EGFR therapy [11]. The gene discussed is EGFR; the disease is colorectal cancer.